MR1-Independent Activation of Human Mucosal-Associated Invariant T Cells by Mycobacteria.

Adolescent Child Cohort Studies Cytokines / immunology Histocompatibility Antigens Class I / immunology Humans Minor Histocompatibility Antigens / immunology Mucosal-Associated Invariant T Cells / immunology Mycobacterium tuberculosis / immunology Receptors, Antigen, T-Cell / immunology

Journal

Journal of immunology (Baltimore, Md. : 1950)
ISSN: 1550-6606
Titre abrégé: J Immunol
Pays: United States
ID NLM: 2985117R

Informations de publication

Date de publication:
01 12 2019
Historique:
received: 18 06 2019
accepted: 18 09 2019
pubmed: 16 10 2019
medline: 28 5 2020
entrez: 16 10 2019
Statut: ppublish

Résumé

Tuberculosis (TB) is the leading cause of mortality from a single infectious agent,

Identifiants

DOI: 10.4049/jimmunol.1900674 PMID: 31611259 PMC: PMC6859375
pubmed: 31611259
pii: jimmunol.1900674
doi: 10.4049/jimmunol.1900674
pmc: PMC6859375
mid: NIHMS1540469
doi:

Substances chimiques

Cytokines 0
Histocompatibility Antigens Class I 0
MR1 protein, human 0
Minor Histocompatibility Antigens 0
Receptors, Antigen, T-Cell 0

Banques de données

ClinicalTrials.gov
['NCT01119521']

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2917-2927

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI129980
Pays : United States
Organisme : NIAID NIH HHS
ID : N01AI70022
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI087915
Pays : United States
Organisme : NIAID NIH HHS
ID : N01AI95383
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI065653
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI134790
Pays : United States
Organisme : NIAID NIH HHS
ID : N01 AI070022
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL083808
Pays : United States

Informations de copyright

Copyright © 2019 The Authors.

Références

J Immunol. 2016 Aug 15;197(4):1100-1110
pubmed: 27412415
J Immunol. 2014 May 15;192(10):4833-43
pubmed: 24733845
PLoS Med. 2016 Oct 25;13(10):e1002152
pubmed: 27780211
Cytometry A. 2011 Feb;79(2):167-74
pubmed: 21265010
Infect Immun. 2018 Nov 20;86(12):
pubmed: 30201702
Vaccine. 2014 Jun 30;32(31):3982-8
pubmed: 24814553
Cell Rep. 2016 Dec 6;17(10):2562-2571
pubmed: 27926861
Front Immunol. 2017 Oct 05;8:1262
pubmed: 29051764
Nat Immunol. 2010 Aug;11(8):701-8
pubmed: 20581831
J Exp Med. 1993 Jul 1;178(1):1-16
pubmed: 8391057
Immunol Rev. 2015 Mar;264(1):154-66
pubmed: 25703558
Immunol Cell Biol. 2018 Jul;96(6):607-617
pubmed: 29451704
J Infect Dis. 2013 Apr;207(7):1084-94
pubmed: 23293360
Trans R Soc Trop Med Hyg. 2015 Jan;109(1):29-35
pubmed: 25573107
Nature. 2017 Jul 6;547(7661):94-98
pubmed: 28636589
Am J Respir Crit Care Med. 2010 Oct 15;182(8):1073-9
pubmed: 20558627
Immunity. 2016 Jan 19;44(1):32-45
pubmed: 26795251
Immunology. 2015 Jul;145(3):443-53
pubmed: 25752900
J Virol. 2000 Dec;74(23):11230-9
pubmed: 11070021
Immunol Cell Biol. 2018 May;96(5):507-525
pubmed: 29437263
J Exp Med. 1999 Jun 21;189(12):1907-21
pubmed: 10377186
PeerJ. 2016 Feb 11;4:e1513
pubmed: 26893956
J Leukoc Biol. 2016 Jul;100(1):233-40
pubmed: 27034405
Sci Immunol. 2018 Jul 13;3(25):
pubmed: 30006464
Mucosal Immunol. 2017 May;10(3):802-813
pubmed: 27759023
Clin Infect Dis. 2014 Feb;58(4):470-80
pubmed: 24336911
J Immunol. 2015 Jul 15;195(2):587-601
pubmed: 26063000
Nat Biotechnol. 2014 Jul;32(7):684-92
pubmed: 24952902
Proc Natl Acad Sci U S A. 2019 Apr 30;116(18):8995-9001
pubmed: 30992377
Immunity. 2019 Jun 18;50(6):1335-1336
pubmed: 31216453
Nature. 2012 Nov 29;491(7426):717-23
pubmed: 23051753
Nat Commun. 2016 Jun 23;7:11653
pubmed: 27337592
Nat Commun. 2016 Aug 16;7:12506
pubmed: 27527800
JCI Insight. 2016 Jun 2;1(8):null
pubmed: 27331143
Eur J Immunol. 2014 Jan;44(1):195-203
pubmed: 24019201
Nat Commun. 2014 May 15;5:3866
pubmed: 24832684
Cell Rep. 2014 Nov 6;9(3):1075-88
pubmed: 25437561
J Immunol Methods. 2015 Feb;417:22-33
pubmed: 25523923
Commun Biol. 2019 Jun 5;2:203
pubmed: 31231693
J Infect Dis. 2015 Feb 1;211(3):338-46
pubmed: 25108027
Blood. 2012 Jan 12;119(2):422-33
pubmed: 22086415
Hum Immunol. 2015 Sep;76(9):607-14
pubmed: 26382249
Nat Commun. 2018 Jan 17;9(1):253
pubmed: 29343684
Immunol Cell Biol. 2018 Jul;96(6):573-587
pubmed: 29656544
J Infect Dis. 2016 Sep 1;214(5):659-64
pubmed: 27247343
Proc Natl Acad Sci U S A. 2018 Dec 4;115(49):E11513-E11522
pubmed: 30442667
Cell Host Microbe. 2016 Jan 13;19(1):44-54
pubmed: 26764596
PLoS Biol. 2010 Jun 29;8(6):e1000407
pubmed: 20613858
Nat Commun. 2016 Apr 12;7:11290
pubmed: 27068708
Tuberculosis (Edinb). 2015 May;95(3):267-74
pubmed: 25837440
J Exp Med. 2014 Jul 28;211(8):1601-10
pubmed: 25049333
Nature. 2017 Jul 6;547(7661):89-93
pubmed: 28636592
Lancet. 2016 Jun 4;387(10035):2312-2322
pubmed: 27017310
Front Immunol. 2015 Jun 16;6:303
pubmed: 26136743
Nature. 2014 May 15;509(7500):361-5
pubmed: 24695216
Nat Immunol. 2015 Nov;16(11):1114-23
pubmed: 26482978
J Immunol Methods. 2004 Aug;291(1-2):185-95
pubmed: 15345316
Nat Commun. 2019 Feb 8;10(1):687
pubmed: 30737409
J Immunol. 2008 Mar 1;180(5):3569-77
pubmed: 18292584
PLoS One. 2011 Mar 29;6(3):e17984
pubmed: 21479236
Mucosal Immunol. 2015 Mar;8(2):429-40
pubmed: 25269706

Auteurs

Sara Suliman (S)

South African Tuberculosis Vaccine Initiative, University of Cape Town, Cape Town 7925, South Africa; ssuliman1@bwh.harvard.edu.
Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town 7925, South Africa.
Division of Immunology, Department of Pathology, University of Cape Town, Cape Town 7925, South Africa.
Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115.
ORCID: 0000-0002-5154-576X

Melissa Murphy (M)

South African Tuberculosis Vaccine Initiative, University of Cape Town, Cape Town 7925, South Africa.
Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town 7925, South Africa.
Division of Immunology, Department of Pathology, University of Cape Town, Cape Town 7925, South Africa.
ORCID: 0000-0001-9906-0713

Munyaradzi Musvosvi (M)

South African Tuberculosis Vaccine Initiative, University of Cape Town, Cape Town 7925, South Africa.
Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town 7925, South Africa.
Division of Immunology, Department of Pathology, University of Cape Town, Cape Town 7925, South Africa.

Anele Gela (A)

South African Tuberculosis Vaccine Initiative, University of Cape Town, Cape Town 7925, South Africa.
Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town 7925, South Africa.
Division of Immunology, Department of Pathology, University of Cape Town, Cape Town 7925, South Africa.

Erin W Meermeier (EW)

Department of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, OR 97239.

Hennie Geldenhuys (H)

South African Tuberculosis Vaccine Initiative, University of Cape Town, Cape Town 7925, South Africa.
Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town 7925, South Africa.
Division of Immunology, Department of Pathology, University of Cape Town, Cape Town 7925, South Africa.

Christiaan Hopley (C)

South African Tuberculosis Vaccine Initiative, University of Cape Town, Cape Town 7925, South Africa.
Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town 7925, South Africa.
Division of Immunology, Department of Pathology, University of Cape Town, Cape Town 7925, South Africa.

Asma Toefy (A)

South African Tuberculosis Vaccine Initiative, University of Cape Town, Cape Town 7925, South Africa.
Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town 7925, South Africa.
Division of Immunology, Department of Pathology, University of Cape Town, Cape Town 7925, South Africa.

Nicole Bilek (N)

South African Tuberculosis Vaccine Initiative, University of Cape Town, Cape Town 7925, South Africa.
Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town 7925, South Africa.
Division of Immunology, Department of Pathology, University of Cape Town, Cape Town 7925, South Africa.

Ashley Veldsman (A)

South African Tuberculosis Vaccine Initiative, University of Cape Town, Cape Town 7925, South Africa.
Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town 7925, South Africa.
Division of Immunology, Department of Pathology, University of Cape Town, Cape Town 7925, South Africa.

Willem A Hanekom (WA)

South African Tuberculosis Vaccine Initiative, University of Cape Town, Cape Town 7925, South Africa.
Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town 7925, South Africa.
Division of Immunology, Department of Pathology, University of Cape Town, Cape Town 7925, South Africa.

John L Johnson (JL)

Tuberculosis Research Unit, Case Western Reserve University School of Medicine, Cleveland, OH 44106.
Department of Medicine, Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center, Cleveland, OH 44106.
ORCID: 0000-0003-1783-0476

W Henry Boom (WH)

Tuberculosis Research Unit, Case Western Reserve University School of Medicine, Cleveland, OH 44106.
Department of Medicine, Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center, Cleveland, OH 44106.
ORCID: 0000-0001-5760-9595

Gerlinde Obermoser (G)

Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, CA 94305; and.
Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305.
ORCID: 0000-0003-4349-5149

Huang Huang (H)

Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, CA 94305; and.
Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305.

Mark Hatherill (M)

South African Tuberculosis Vaccine Initiative, University of Cape Town, Cape Town 7925, South Africa.
Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town 7925, South Africa.
Division of Immunology, Department of Pathology, University of Cape Town, Cape Town 7925, South Africa.
ORCID: 0000-0003-3491-1809

David M Lewinsohn (DM)

Department of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, OR 97239.

Elisa Nemes (E)

South African Tuberculosis Vaccine Initiative, University of Cape Town, Cape Town 7925, South Africa.
Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town 7925, South Africa.
Division of Immunology, Department of Pathology, University of Cape Town, Cape Town 7925, South Africa.
ORCID: 0000-0003-1662-4961

Thomas J Scriba (TJ)

South African Tuberculosis Vaccine Initiative, University of Cape Town, Cape Town 7925, South Africa.
Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town 7925, South Africa.
Division of Immunology, Department of Pathology, University of Cape Town, Cape Town 7925, South Africa.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adolescent › MR1-Independent Activation of Human...
questionsmedicales.fr › Personnes › Tranches d'âge › Enfant › MR1-Independent Activation of Human...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › MR1-Independent Activation of Human...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › MR1-Independent Activation of Human...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Isoantigènes › Antigènes d'histocompatibilité › Antigènes d'histocompatibilité de classe I › MR1-Independent Activation of Human...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › MR1-Independent Activation of Human...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Isoantigènes › Antigènes d'histocompatibilité › Antigènes mineurs d'histocompatibilité › MR1-Independent Activation of Human...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Sous-populations de lymphocytes T › Cellules T invariantes associées aux muqueuses › MR1-Independent Activation of Human...
questionsmedicales.fr › Bactéries › Bactéries à Gram positif › Bâtonnets à Gram positif › Bâtonnets asporogènes à Gram positif › Bâtonnets asporogènes réguliers à Gram positif › Mycobacteriaceae › Mycobacterium › Mycobacterium tuberculosis › MR1-Independent Activation of Human...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs immunologiques › Récepteurs aux antigènes › Récepteurs aux antigènes des cellules T › MR1-Independent Activation of Human...